RxDoctor Payments Data

Jennifer Vega

Family · South Miami, FLNPI 1609384981

Payments from drug & device makers

$19,077in general payments, 2019–2025

Across 1,112 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • UCB, Inc.$2K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Novartis$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $6K from 25 others

What the payments were for

  • Food & beverage$19,013100%
  • Education$640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,077 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$190,439
Medicare patients
93
Services billed
14,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab85$732,653
Cosentyx Unoready PenSecukinumab39$426,054
Cimzia (2 Pack)Certolizumab Pegol27$154,648
Taltz AutoinjectorIxekizumab12$83,413
ProliaDenosumab14$24,336
Mycophenolate Mofetil69$6,172
Hydroxychloroquine Sulfate258$3,511
Vitamin D2Ergocalciferol (Vitamin D2)255$2,550
Tizanidine Hcl266$2,244
Pilocarpine Hcl43$2,171
MethotrexateMethotrexate Sodium253$2,002
Sulfasalazine150$1,991
Methylprednisolone99$1,661
Cevimeline Hcl15$1,659
Colchicine28$1,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$2,133$154,64827 claims
AmgenProlia$3,537$24,33614 claims
Scilex Pharmaceuticals Inc.Colchicine$151$1,23828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →